Eli Lilly and Company (NYSE:LLY) Posts Earnings Results, Beats Expectations By $0.06 EPS

Eli Lilly and Company (NYSE:LLY) released its quarterly earnings data on Wednesday. The company reported $7.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06, FiscalAI reports. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same period in the previous year, the company posted $5.32 EPS. The firm’s revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company updated its FY 2026 guidance to 33.500-35.000 EPS.

Here are the key takeaways from Eli Lilly and Company’s conference call:

• Financial strength: Lilly reported 2025 revenue of $65.2 billion (+45%) and EPS of $24.21 (+86%), and guided 2026 revenue to $80–83 billion with EPS of $33.50–35.00, signaling material top‑ and bottom‑line growth expectations.
• Orforglipron and oral expansion: Lilly submitted Orforglipron for obesity in the U.S. and 40+ countries, expects a U.S. launch in Q2 2026, and is positioning oral GLP‑1s as market‑expanding rather than purely cannibalistic.
• Retatrutide efficacy: Phase 3 TRIUMPH‑4 showed retatrutide 12 mg produced an average 29% weight loss at 68 weeks and large pain/function improvements in knee osteoarthritis, supporting potential use for patients with severe obesity and comorbidities.
• Access and pricing tradeoffs: Lilly agreed with the U.S. government to offer obesity medicines to Medicare/Medicaid patients at a $50/month out‑of‑pocket copay (effective by July 1, 2026), while warning that price concessions will drag 2026 growth in the low‑ to mid‑teens but should be offset by volume expansion over time.
• R&D and pipeline momentum: The company highlighted broad late‑stage progress—including full FDA approval and label expansion for pirtobrutinib and ~80% PFS risk reduction in a frontline CLL study—alongside 36 active Phase 3 programs and multiple new trial starts and BD deals.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded up $98.93 during trading hours on Wednesday, reaching $1,102.39. 4,043,032 shares of the stock traded hands, compared to its average volume of 3,093,905. The company has a market capitalization of $1.04 trillion, a P/E ratio of 54.00, a price-to-earnings-growth ratio of 0.79 and a beta of 0.39. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95. The company’s 50-day simple moving average is $1,054.28 and its two-hundred day simple moving average is $893.81.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q4 top‑and‑bottom‑line beat — Q4 revenue ~$19.3B (up ~43% YoY) and adjusted EPS $7.54, comfortably ahead of many forecasts; investors pushed the stock higher on the clear beat. Eli Lilly sees 2026 profit above estimates on weight‑loss drug demand (Reuters)
• Positive Sentiment: Bullish FY‑2026 guidance — company set EPS guidance of 33.50–35.00 and revenue guidance $80–83B (above consensus), signaling continued strong growth into 2026. Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance (PR Newswire)
• Positive Sentiment: Robust GLP‑1 sales driving momentum — Mounjaro and Zepbound posted steep revenue gains (reported splits in coverage) and management cited them as the primary growth engines behind the beat and guidance. Eli Lilly blows past quarterly estimates (CNBC)
• Positive Sentiment: Analyst support and market cap milestone — major firms (e.g., Goldman Sachs) reaffirmed bullish views and the company returned above a $1 trillion market cap, reinforcing investor confidence. Goldman Sachs maintains a buy rating (MarketScreener)
• Neutral Sentiment: Capacity and manufacturing expansion — Lilly is investing in U.S. injectable manufacturing ( ~$3.5B site ), supporting supply for growing demand but representing near‑term capital spend. Eli Lilly Announces New $3.5 Billion Manufacturing Facility in Pennsylvania (PharmExec)
• Neutral Sentiment: Pipeline and M&A activity — deals (e.g., Seamless Therapeutics hearing‑loss agreement, small stakes/IPO moves) expand long‑term optionality but are not immediate revenue drivers. Eli Lilly Is Getting Into the Hearing Loss Market (The Motley Fool)
• Negative Sentiment: U.S. pricing pressure and competition — management flagged U.S. pricing headwinds, and competitive moves (Novo Nordisk’s new pill launch and its own guidance shakeup) add uncertainty to pricing and market share dynamics. These are longer‑term risks that could blunt margin upside. Eli Lilly vs. Novo Nordisk coverage (WSJ)
• Negative Sentiment: Rising R&D and capital spending could pressure near‑term margins despite top‑line strength — analysts noted elevated R&D/capex as a potential drag. Q4 preview noting R&D cost risks (Benzinga)

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in LLY. FSA Wealth Management LLC grew its holdings in shares of Eli Lilly and Company by 4.0% during the 3rd quarter. FSA Wealth Management LLC now owns 309 shares of the company’s stock valued at $236,000 after purchasing an additional 12 shares during the last quarter. Shay Capital LLC lifted its stake in Eli Lilly and Company by 4.5% in the second quarter. Shay Capital LLC now owns 350 shares of the company’s stock worth $273,000 after purchasing an additional 15 shares during the last quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. boosted its position in Eli Lilly and Company by 1.2% during the third quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 1,710 shares of the company’s stock valued at $1,305,000 after buying an additional 20 shares during the period. High Falls Advisors Inc grew its stake in shares of Eli Lilly and Company by 3.6% during the second quarter. High Falls Advisors Inc now owns 608 shares of the company’s stock valued at $474,000 after buying an additional 21 shares during the last quarter. Finally, Graney & King LLC increased its holdings in shares of Eli Lilly and Company by 14.6% in the second quarter. Graney & King LLC now owns 181 shares of the company’s stock worth $141,000 after buying an additional 23 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Morgan Stanley increased their price target on shares of Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the stock an “overweight” rating in a report on Monday, November 24th. Wall Street Zen cut shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Daiwa Capital Markets set a $1,230.00 price target on shares of Eli Lilly and Company and gave the company a “buy” rating in a research report on Tuesday, December 16th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Eli Lilly and Company in a research report on Monday, December 22nd. Finally, National Bankshares set a $1,286.00 price objective on Eli Lilly and Company in a research note on Monday, December 1st. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,162.75.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.